Cart
0
You may also like
Most people think of melatonin as a mild sleep gummy you take for jet lag. In that context, a standard dose is maybe 1 mg to 3 mg. But in oncology research, the conversation changes completely. We stop talking about single digits and start looking at pharmacological doses—anywhere from 20 mg to 100 mg a day.
At these levels, melatonin stops acting like a simple sleep hormone and starts acting like a metabolic drug that targets the fuel source of cancer cells.
Starving the Cancer (The Warburg Effect)
To understand why high doses matter, you have to look at how cancer eats.
Cancer cells break the metabolic rules. Healthy cells are efficient; they use oxygen to burn fuel cleanly. Cancer cells are wasteful. Even when they have plenty of oxygen, they prefer to ferment sugar to create energy—a quirk discovered nearly a century ago called the Warburg Effect. This inefficient "sugar hunger" allows them to burn fuel fast and build mass quickly.
High-dose melatonin essentially throws a wrench in this engine:
-
The Blockade: It inhibits an enzyme called Pyruvate Dehydrogenase Kinase (PDK).
-
The Forced Shift: By blocking PDK, melatonin forces the cancer cell to stop fermenting sugar and instead route fuel through the mitochondria (the cell's power plant).
-
The Backfire: This is where the trap snaps shut. Cancer cells aren't built to handle this efficient energy production anymore. The sudden shift causes a massive buildup of Reactive Oxygen Species (ROS)—essentially cellular rust—within the mitochondria. This toxic stress overloads the cell and can trigger it to self-destruct.
A Force Multiplier for the Immune System
Beyond metabolism, melatonin seems to act as a partner for the immune system. Research has looked at its synergy with Interleukin-2 (IL-2), a powerful therapy that activates cancer-killing T-cells.
The problem with IL-2 has always been toxicity; high doses can be dangerous. Studies suggest that adding melatonin might allow doctors to use lower, safer doses of IL-2 while keeping its cancer-fighting punch intact.
What the Data Actually Says
The science is fascinating, but does it work in patients? The evidence is a mix of high hopes and necessary caution.
-
The Lissoni Trials: For decades, Dr. Paolo Lissoni in Italy ran trials that reported massive benefits. In patients with solid tumors (like lung and colon cancer), those taking 20 mg of melatonin alongside chemo often saw their 1-year survival rates double compared to those on chemo alone.
-
The Modern Reality Check: A 2025 Cochrane review took a harder, more skeptical look. After filtering out older studies that might be biased, they concluded that melatonin is definitely useful for supportive care—it helps reduce the exhaustion and nerve damage from chemo—but they weren't ready to confirm a survival benefit without more rigorous, large-scale testing.
-
The Dose Question: Interestingly, we might not be using enough. One trial found that patients who stopped responding to 20 mg could re-establish control over their tumor by bumping the dose up to 100 mg, suggesting that aggressive tumors might require aggressive dosing to break their metabolic resistance.
While it’s not a magic cure, the evidence points to high-dose melatonin as a low-toxicity tool that can stress tumor metabolism and protect the patient from the harsh side effects of standard treatment.
